Table 4.
Biophysical characterization of chimeric and humanized mAb.
| mAb ID | SEC-HPLC |
HIC-HPLC |
DSF |
|
|---|---|---|---|---|
| % mAb Monomer | % Aggregate | Retention Time (min)* | Fab Tm (°C) | |
| HY6-F9_Ch | 98.0 | 2.0 | 14.88 | 77.0 |
| HY6-F9_Hu | >99.5 | <0.5 | 16.17 | 81.5 |
| HY6-F9_Hu (NQ) | >99.5 | <0.5 | 14.51 | 78.5 |
| HY6-F9_Hu (GR) | >99.5 | <0.5 | 15.73 | 78.7 |
| HY11-7E1_Ch | 98.5 | 1.5 | 13.01 | 72.5–76.5 |
| HY11-7E1_Hu | >99.5 | <0.5 | 13.11 | 78.0 |
| HY11-7E1_Hu (DE) | >99.5 | <0.5 | 13.06 | 80.5 |
| HY11-7E1_Hu (GV) | >99.5 | <0.5 | 13.07 | 77.6 |
| In-house rituximab | 99.2 | 0.8 | 13.97 | Not Tested |
*HIC-HPLC salt gradient ends at 16.67 min.